Charles River Laboratories Intl. Inc (CRL) Expected to Announce Earnings of $1.26 Per Share

Equities research analysts predict that Charles River Laboratories Intl. Inc (NYSE:CRL) will post earnings per share of $1.26 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with estimates ranging from $1.23 to $1.29. Charles River Laboratories Intl. posted earnings of $1.21 per share in the same quarter last year, which would indicate a positive year over year growth rate of 4.1%. The firm is expected to report its next quarterly earnings report before the market opens on Tuesday, February 13th.

On average, analysts expect that Charles River Laboratories Intl. will report full year earnings of $5.14 per share for the current financial year, with EPS estimates ranging from $5.10 to $5.16. For the next year, analysts anticipate that the business will post earnings of $5.57 per share, with EPS estimates ranging from $5.45 to $5.86. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the company earned $1.18 earnings per share. Charles River Laboratories Intl.’s revenue for the quarter was up 9.0% on a year-over-year basis.

A number of analysts have recently weighed in on CRL shares. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Credit Suisse Group restated a “neutral” rating and issued a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories Intl. in a research note on Monday, October 16th. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, November 13th. Argus started coverage on shares of Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price objective for the company. Finally, SunTrust Banks restated a “buy” rating and issued a $113.00 price objective on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories Intl. has a consensus rating of “Hold” and an average target price of $112.58.

Shares of Charles River Laboratories Intl. (NYSE:CRL) opened at $100.43 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories Intl. has a one year low of $81.56 and a one year high of $119.05. The firm has a market cap of $4,775.46, a price-to-earnings ratio of 24.50, a PEG ratio of 1.48 and a beta of 0.74.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, Director Online Communications Bdirect sold 131,000 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00. Insiders have sold 1,195,673 shares of company stock worth $2,914,046 in the last ninety days. 2.20% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the business. YorkBridge Wealth Partners LLC increased its holdings in Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its holdings in Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after buying an additional 548 shares during the period. Advisor Group Inc. increased its holdings in Charles River Laboratories Intl. by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after buying an additional 945 shares during the period. Zions Bancorporation bought a new stake in Charles River Laboratories Intl. in the 3rd quarter valued at $212,000. Finally, Koch Industries Inc. bought a new stake in Charles River Laboratories Intl. in the 2nd quarter valued at $240,000. 97.47% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Charles River Laboratories Intl. Inc (CRL) Expected to Announce Earnings of $1.26 Per Share” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2018/02/08/charles-river-laboratories-intl-inc-crl-expected-to-announce-earnings-of-1-26-per-share.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply